Literature DB >> 22100657

Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.

Xiaolin Li1, Huaqi Zhang, Ligang Xing, Honglian Ma, Peng Xie, Lin Zhang, Xiangying Xu, Jinbo Yue, Xindong Sun, Xudong Hu, Ming Chen, Wengui Xu, Lusheng Chen, Jinming Yu.   

Abstract

PURPOSE: Accurate staging of mediastinal lymph nodes metastases is critical for determining the application of stereotactic body radiation therapy (SBRT) for patients with early stage non-small cell lung cancer (NSCLC). In this multicenter study the accuracy of (18)F-FDG PET/CT to detect lymph node metastases was evaluated for early stage NSCLC.
MATERIALS AND METHODS: The data from the patients with stage1 NSCLC who received preoperative (18)F-FDG PET/CT staging and radical surgery was retrospectively reviewed of five centers from February 2004 to August 2010. The lymph node metastases were confirmed histopathologically after radical surgery. And the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were calculated for PET/CT staging.
RESULTS: Two hundred patients were enrolled. The sensitivity, specificity, accuracy, PPV and NPV for lymph node metastases on PET/CT were 44%, 83%, 78%, 29% and 91%, respectively. There were eight and 19 cases positive for lymph node metastases with central (n=62) and peripheral (n=138) NSCLC (P>0.05), respectively.
CONCLUSION: (18)F-FDG PET/CT was specific in N(0) staging for T(1-2) NSCLC. The NPV was about 91% in clinical N(0) patients, suggested that (18)F-FDG PET/CT may help to accurately stage N(0) patients and thus identify patients for SBRT.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22100657     DOI: 10.1016/j.radonc.2011.10.016

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  22 in total

1.  Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.

Authors:  Gregor Sommer; Mark Wiese; Leopold Winter; Claudia Lenz; Markus Klarhöfer; Flavio Forrer; Didier Lardinois; Jens Bremerich
Journal:  Eur Radiol       Date:  2012-07-09       Impact factor: 5.315

2.  N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience.

Authors:  A A Kohan; J A Kolthammer; J L Vercher-Conejero; C Rubbert; S Partovi; R Jones; K A Herrmann; P Faulhaber
Journal:  Eur Radiol       Date:  2013-06-14       Impact factor: 5.315

3.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Kai Obayashi; Seshiru Nakazawa; Seiichi Kakegawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Masahiko Nishiyama; Izumi Takeyoshi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

4.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

Review 5.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

6.  The diagnostic ability of 18F-FDG PET/CT for mediastinal lymph node staging using 18F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer.

Authors:  Jeong Won Lee; Eun Young Kim; Dae Joon Kim; Jae-Hoon Lee; Won Jun Kang; Jong Doo Lee; Mijin Yun
Journal:  Eur Radiol       Date:  2016-03-04       Impact factor: 5.315

7.  The impact of pathologic staging of the hilar/mediastinal nodes on outcomes in patients with early-stage NSCLC receiving stereotactic body radiotherapy.

Authors:  Brandon T Mullins; Dominic T Moore; M Patricia Rivera; Lawrence B Marks; Jason Akulian; Kevin A Pearlstein; Kyle Wang; Allen C Burks; Ashley A Weiner
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

8.  Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer.

Authors:  John Cuaron; Mark Dunphy; Andreas Rimner
Journal:  Front Oncol       Date:  2013-01-03       Impact factor: 6.244

9.  Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer.

Authors:  Tetsuya Inoue; Norio Katoh; Rikiya Onimaru; Shinichi Shimizu; Kazuhiko Tsuchiya; Ryusuke Suzuki; Jun Sakakibara-Konishi; Naofumi Shinagawa; Satoshi Oizumi; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2013-03-21       Impact factor: 3.481

10.  Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer.

Authors:  Percy Lee; Patrick Kupelian; Johannes Czernin; Partha Ghosh
Journal:  Front Oncol       Date:  2012-07-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.